Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback